))
Unveiling the Latest Advancements in CKD-Associated Pruritus Care
Manage episode 456468875 series 3381434
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
CME credits: 0.25
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/unveiling-the-latest-advancements-in-ckd-associated-pruritus-care/26636/
Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA. =
…
continue reading
Valid until: 18-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/unveiling-the-latest-advancements-in-ckd-associated-pruritus-care/26636/
Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA. =
461 episoade
Distribuie
